Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Two-centre, Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Adult Subjects With Moderate to Severe Asthma.

Next Previous
Trial Profile

A Phase II, Two-centre, Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Adult Subjects With Moderate to Severe Asthma.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASM 8 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Syntara Limited

Most Recent Events

  • 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
  • 16 Nov 2011 New source identified and integrated (European Clinical Trials Database).
  • 23 Jun 2011 Planned initiation date (May 2013) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top